Stockscreener 앱 받기
35.78
5.14%
-1.94
시간 외 거래:
35.08
-0.70
-1.96%
Nektar Therapeutics 주식(NKTR)의 최신 뉴스
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research
Nektar Therapeutics (NKTR) Could Be 72% Undervalued On New Rezpegaldesleukin Data - Simply Wall Street
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Roche Holding AG (OtherRHHVF) and Henry Schein (HSIC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Roche Holding AG (OtherRHHVF) and Henry Schein (HSIC) - The Globe and Mail
Nektar Therapeutics Initiated at Neutral by UBS - Moomoo
UBS Initiates Nektar Therapeutics(NKTR.US) With Hold Rating, Announces Target Price $53 - Moomoo
Leerink Highlights Nektar Therapeutics (NKTR) as Top Emerging Te - GuruFocus
Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology - Seeking Alpha
Nektar Therapeutics Price Target Announced at $53.00/Share by UBS - Moomoo
Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case - Yahoo Finance
Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target - marketscreener.com
Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target - Yahoo Finance
UBS initiates Nektar Therapeutics stock at Neutral on catalyst timing By Investing.com - Investing.com Nigeria
Raymond James Initiates Nektar Therapeutics at Market Perform - Yahoo Finance
Lawsuit Win Could Be A Game Changer For Nektar Therapeutics (NKTR) - Simply Wall Street
Nektar Therapeutics stock faces a cash runway into 2028 - AD HOC NEWS
Is Nektar Therapeutics (NKTR) Cheap As Rezpegaldesleukin Data Supports Phase 3 Plans? - Simply Wall Street
Nektar Therapeutics (NKTR) stock price, news, quote and history - Yahoo Finance Singapore
Nektar Therapeutics (NKTR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang - Yahoo Finance
Nektar's Phase 2b Data Shows Durable Eczema, Alopecia Response - Streetwise Reports
Nektar Therapeutics stock analysis: oversold technicals meet binary clinical risk - Investing.com
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - Moomoo
Nektar Therapeutics (NKTR) Shareholder/Analyst CallSlideshow (NASDAQ:NKTR) 2026-10-03 - Seeking Alpha
Nektar Therapeutics Company Profile & Introduction - Moomoo
Two Seas Capital LP Adds Nektar Therapeutics (NKTR) -- Shares Look 766% Overvalued on GF Value - GuruFocus
Nektar Therapeutics Stock Price Forecast. Should You Buy NKTR? - StockInvest.us
Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More (NKTR) - Seeking Alpha
HC Wainwright & Co. reiterates Buy rating on Nektar Therapeutics, $185 price target - TradingView
Nektar Therapeutics (NasdaqCM:NKTR) Stock Forecast & Analyst Predictions - Simply Wall Street
Nektar Discloses Phase 2b Data for REZPEG in Severe Alopecia Areata - The Clinical Trial Vanguard
Jefferies sets $150 target for Nektar Therapeutics amid promising alopecia drug data despite stock drop. - Pluang
NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge - Yahoo Finance
Jefferies Analyst Defends Nektar Therapeutics (NKTR) Amid 21% St - GuruFocus
Why This Biotech Took A 21% Hit On Promising Alopecia Results - Investor's Business Daily
Nektar Therapeutics (NKTR) Shares Drop After Rezpegaldesleukin T - GuruFocus
William Blair Reaffirms Outperform on Nektar Therapeutics (NKTR) Amid Rezpeg Data Advances - GuruFocus
Nektar Therapeutics (NKTR) Stock Forecasts - Yahoo! Finance Canada
This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking? - Barron's
Nektar Therapeutics Down Nearly 21%, on Pace for Largest Percent Decrease Since February 2023 -- Data Talk - Moomoo
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial - Yahoo Finance
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 - PR Newswire
Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment - TradingView
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Nektar Therapeutics (NKTR) and Stryker (SYK) - The Globe and Mail
/UPDATE -- Nektar Therapeutics/ - Yahoo Finance
Asset turnover of Nektar Therapeutics – HAN:ITH0 - TradingView
How Investors May Respond To Nektar Therapeutics (NKTR) New Phase 2b Data Presentations - webull.com
How New Rezpegaldesleukin Durability and Mechanistic Data Could Impact Nektar Therapeutics (NKTR) Investors - Yahoo Finance
What Could Nektar Therapeutics (NKTR) New Rezpegaldesleukin Data Mean For Its Case? - Yahoo Finance
How Investors May Respond To Nektar Therapeutics (NKTR) New Phase 2b Data Presentations - Simply Wall Street
6.12%
0.14%
자본화:
|
볼륨(24시간):